source
- Superluminal Medicines raises $60M Series B to launch Phase 1 trial of genetic obesity therapySuperluminal Medicines, a Boston‑based biotech, announced it has closed a $60 million Series B financing round. The capital will fund the company’s first‑in‑human study of its genetic obesity candi…
- Ultragenyx's Angelman syndrome drug fails Phase 3 trial, halting developmentUltragenyx reported that its experimental antisense oligonucleotide designed for Angelman syndrome did not meet primary endpoints in a Phase 3 study. The trial, which enrolled patients with the ra…